A disruptive innovation
The rPRO™ platform, a disruptive innovation, uses genetic recombination to express a protein in mammal milk that can be used in human medicine. The protein is then isolated, purified and made safe using the highest pharmaceutical standards. rPRO™ is a robust, productive technology, with an excellent economic profile, largely because it increases production greatly while keeping costs down. For this reason rPRO™ may help to improve access to medicinal products to the largest number of patients.
A new innovative activated Factor VII
On the 6th April 2020, the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for the new recombinant coagulation Factor VIIa, coagulation factor VIIa (recombinant). This LFB recombinant activated Factor VII, eg the entity Eptacog Beta, will be produced by rPRO™, and has been developed to treat certain forms of haemophilia. It would be the first alternative in the context of treatments using Factor VIIa in over 20 years.
rPRO™ technology is used by the US subsidiary LFB USA, which is developing and producing recombinant proteins with this platform. The bioproduction site of LFB USA devoted to recombinant proteins, is located in Massachusetts (USA).